[
    {
        "id": "osp-1177",
        "type": "article-journal",
        "title": "HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors",
        "author": [
            {
                "family": "Arafah",
                "given": "Maha"
            },
            {
                "family": "Kfoury",
                "given": "Hala K."
            },
            {
                "family": "Zaidi",
                "given": "Shaesta N."
            }
        ],
        "URL": "https://omanscience.com/en/articles/her2-neu-immunostaining-in-invasive-breast-cancer-analysis-of-false-positive-factors",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2010
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2010.78",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "Objectives: HER2/neu gene amplification by Fluorescent in situ hybridization and protein expression by immunohistochemistry have been used for prognosis and guidance for the treatment of invasive ductal carcinoma of the breast with Trastuzumab. False positive results are a significant problem where immunohistochemistry is exclusively used to test HER2/neu protein over expression. A minority of cases of breast cancer scoring HER2 (3+) by immunohistochemistry using Hercep test may not be associated with amplification of the HER2/neu gene by FISH, a test which is a more specific and sensitive than immunohistochemistry. This study aims to examine the factors contributing to false positive results by immunohistochemistry and subsequently not showing HER2/neu gene amplification by FISH analysis."
    }
]